US Stock MarketDetailed Quotes
BIVI BioVie
- 2.640
- +0.050+1.93%
Close Dec 13 16:00 ET
- 2.680
- +0.040+1.52%
Post 19:58 ET
46.91MMarket Cap-0.52P/E (TTM)
2.675High2.410Low1.86MVolume2.600Open2.590Pre Close4.76MTurnover13.21%Turnover RatioLossP/E (Static)17.77MShares33.10052wk High3.33P/B37.21MFloat Cap1.04052wk Low--Dividend TTM14.10MShs Float460.977Historical High--Div YieldTTM10.23%Amplitude1.040Historical Low2.557Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
BioVie Stock Forum
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie (NASDAQ: BIVI) announced the acceptance of an abstract detailing their planned Phase 2 trial of bezisterim for Long COVID treatment at the Demystifying Long COVID International Conference in Barcelona. The study, fully funded by the U.S. Department of Defense, will be a double-blind, randomized, placebo-controlled tri...
📊⚡️📊
Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioVie Inc (NASDAQ: BIVI) announced the pricing of a registered direct offering of 1,146,000 shares of common stock at $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds. The offering, priced at-the-market under Nasdaq rules, is expected to close around October 29, 2024. The company plans to use the net proceeds for working capital and general corpo...
No comment yet